Yuyu Pharma Valuation Multiples

Yuyu Pharma is valued at $44M as of November 2026, a 0.5x revenue multiple. In the last fiscal year, Yuyu Pharma revenue was $106M and Yuyu Pharma EBITDA was $13M.

Yuyu Pharma Overview

About Yuyu Pharma

Yuyu Pharma Inc. manufactures and markets medicines. The product is the medicines for Alzheimer's, which accounts for 45% of total revenue. The company also engages in health aid foods, rental of oxygen generator and analysis of medicines.


Founded

1941

HQ

South Korea

Employees

N/A

Website

yuyu.co.kr

Financials (Last FY)

Revenue: $106M
EBITDA: $13M

EV

$55M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Yuyu Pharma Financials

Yuyu Pharma reported last fiscal year revenue of $106M and EBITDA of $13M.

In the same fiscal year, Yuyu Pharma generated $40M in gross profit, $13M in EBITDA, and $6M in net income.


Yuyu Pharma P&L

In the most recent fiscal year, Yuyu Pharma reported revenue of $106M and EBITDA of $13M.

Yuyu Pharma is profitable as of last fiscal year, with gross margin of 38%, EBITDA margin of 12%, and net margin of 6%.

See analyst estimates for Yuyu Pharma
Last FY2025202620272028
Revenue$106M$106M
Gross Profit$40M$40M
Gross Margin38%38%
EBITDA$13M$13M
EBITDA Margin12%12%
EBIT Margin8%8%
Net Profit$6M$6M
Net Margin6%6%
Net Debt($876K)-

Financial data powered by Morningstar, Inc.

Yuyu Pharma Stock Performance

Yuyu Pharma has current market cap of $44M, and enterprise value of $55M.

Market Cap Evolution


Yuyu Pharma's stock price is $2.79.

Yuyu Pharma has an EPS (earnings per share) of $0.39.

See more trading valuation data for Yuyu Pharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$55M$44M0.7%---$0.39

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Yuyu Pharma Valuation Multiples

Yuyu Pharma trades at 0.5x EV/Revenue multiple, and 4.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Yuyu Pharma

Yuyu Pharma Financial Valuation Multiples

As of November 19, 2026, Yuyu Pharma has market cap of $44M and EV of $55M.

Yuyu Pharma has a P/E ratio of 7.2x.

Last FY2025202620272028
EV/Revenue0.5x0.5x
EV/EBITDA4.3x4.3x
EV/EBIT6.6x6.6x
EV/Gross Profit1.4x1.4x
P/E7.2x7.2x
EV/FCF10.7x10.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Yuyu Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Yuyu Pharma Margins & Growth Rates

In the most recent fiscal year, Yuyu Pharma reported gross margin of 38%, EBITDA margin of 12%, and net margin of 6%.

See estimated margins and future growth rates for Yuyu Pharma

Yuyu Pharma Margins

Last FY2025202720282029
Gross Margin38%38%
EBITDA Margin12%12%
EBIT Margin8%8%
Net Margin6%6%
FCF Margin5%5%

Data powered by FactSet, Inc. and Morningstar, Inc.

Yuyu Pharma Operational KPIs

Access forward-looking KPIs for Yuyu Pharma
Last FY2025202620272028
S&M Expenses to Revenue12%12%
G&A Expenses to Revenue2%2%
R&D Expenses to Revenue3%3%
Opex to Revenue30%30%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Yuyu Pharma Competitors

Yuyu Pharma competitors include J. Molner, OSE Immunotherapeutics, Semnur Pharmaceuticals, Labiana Health, Shield Therapeutics, Elicio Therapeutics, Prescient Therapeutics, Oncoinvent, Intercure and Sangamo Therapeutics.

Most Yuyu Pharma public comparables operate across Biopharmaceuticals.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
J. Molner$1M$960K39.7x-52.2x-
OSE Immunotherapeutics$3M($35M)20.3x7.5x(1.7x)(1.8x)
Semnur Pharmaceuticals-($160M)--(0.4x)-
Labiana Health$83M$12M0.9x0.9x6.5x6.1x
Shield Therapeutics$50M($9M)1.3x1.1x(7.2x)(22.4x)
Elicio Therapeutics-($38M)--(0.7x)-
Prescient Therapeutics------
Oncoinvent$2M($15M)14.4x17.0x(2.3x)(2.3x)

This data is available for Pro users. Sign up to see all Yuyu Pharma competitors and their valuation data.

Start Free Trial

Investments by Yuyu Pharma

Yuyu Pharma has invested in 2 companies to date.

Latest investment by Yuyu Pharma was on February 4th 2026. Yuyu Pharma invested in James & Ella in their Strategic investment round.

See VC round multiples

Latest Investments by Yuyu Pharma

James & Ella
Dalan Animal Health
Description
James & Ella produces freeze-dried, shelf-stable raw meals revolutionizing convenient pet nutrition.
Dalan Animal Health is an Athens, Georgia-headquartered biotechnology firm developing RNA interference vaccines against American foulbrood and other bee pathogens. Founded in 2018, the platform targets commercial beekeepers to protect pollination-dependent agriculture.
HQ CountryUnited KingdomUnited States
HQ City
London
Athens, GA
Deal Date4 Feb 20262 Dec 2025
RoundStrategic investmentUndisclosed stage
Raisedundisclosedundisclosed
InvestorsYuyu PharmaYuyu Pharma
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Yuyu Pharma investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Yuyu Pharma

When was Yuyu Pharma founded?Yuyu Pharma was founded in 1941.
Where is Yuyu Pharma headquartered?Yuyu Pharma is headquartered in South Korea.
Is Yuyu Pharma publicly listed?Yes, Yuyu Pharma is a public company listed on Korea Exchange.
What is the stock symbol of Yuyu Pharma?Yuyu Pharma trades under 000220 ticker.
When did Yuyu Pharma go public?Yuyu Pharma went public in 1975.
Who are competitors of Yuyu Pharma?Yuyu Pharma main competitors include J. Molner, OSE Immunotherapeutics, Semnur Pharmaceuticals, Labiana Health, Shield Therapeutics, Elicio Therapeutics, Prescient Therapeutics, Oncoinvent, Intercure, Sangamo Therapeutics.
What is the current market cap of Yuyu Pharma?Yuyu Pharma's current market cap is $44M.
What is the current revenue of Yuyu Pharma?Yuyu Pharma's last fiscal year revenue is $106M.
What is the current EV/Revenue multiple of Yuyu Pharma?Current revenue multiple of Yuyu Pharma is 0.5x.
Is Yuyu Pharma profitable?No, Yuyu Pharma is not profitable.
How many companies Yuyu Pharma has acquired to date?Yuyu Pharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Yuyu Pharma has invested to date?As of November 2026, Yuyu Pharma has invested in 2 companies.
What was the last Yuyu Pharma investment?On 4th February 2026 Yuyu Pharma invested in James & Ella, participating in a Strategic investment round.
In what companies Yuyu Pharma invested in?Yuyu Pharma invested in James & Ella and Dalan Animal Health.

See public comps similar to Yuyu Pharma

Lists including Yuyu Pharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial